Organon & Co. (OGN) Debt Components
- 2026-06-30: Long-term Debt, Current MaturitiesUSD (m); Debt, CurrentUSD (m); Long-term Debt, Excluding Current MaturitiesUSD (m); Long-term DebtUSD (m).
- 2026-06-30: Long-term Debt, Current MaturitiesUSD (m); Debt, CurrentUSD $74.00M; Long-term Debt, Excluding Current MaturitiesUSD $8.48B; Long-term DebtUSD $8.55B.
- 2026-03-31: Long-term Debt, Current MaturitiesUSD (m); Debt, CurrentUSD (m); Long-term Debt, Excluding Current MaturitiesUSD (m); Long-term DebtUSD (m).
- 2026-03-31: Long-term Debt, Current MaturitiesUSD (m); Debt, CurrentUSD $16.00M; Long-term Debt, Excluding Current MaturitiesUSD $8.55B; Long-term DebtUSD $8.57B.
Organon & Co. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Long-term Debt, Current Maturities USD | Debt, Current USD | Long-term Debt, Excluding Current Maturities USD | Long-term Debt USD | Long-Term Debt, Maturity, Year One USD | Long-Term Debt, Maturity, Year Two USD | Long-Term Debt, Maturity, Year Three USD | Long-Term Debt, Maturity, Year Four USD | Long-Term Debt, Maturity, Year Five USD | Long-Term Debt, Maturity, after Year Five USD | Long-Term Debt, Maturity, Remainder of Fiscal Year USD | Long-term Debt, Fair Value USD | Long-term Debt, Weighted Average Interest Rate, over Time pure | Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net USD | Debt Instrument, Unamortized Discount USD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 6 month · 4.90% | (m) | (m) |
| 2026-06-30 | (m) | $74.00M | $8.48B | $8.55B | $61.00M | $3.49B | $9.00M | $21.00M | (m) | (m) | $1.00M | (m) | (m) | $72.00M | (m) |
| 2026-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 3 month · 4.90% | (m) | (m) |
| 2026-03-31 | (m) | $16.00M | $8.55B | $8.57B | $61.00M | $3.50B | $9.00M | $21.00M | (m) | (m) | $1.00M | (m) | (m) | $77.00M | (m) |
| 2025-12-31 | (m) | $16.00M | $8.63B | $8.64B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $81.00M | (m) |
| 2025-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 12 month · 4.90% | (m) | (m) |
| 2025-12-31 | (m) | (m) | (m) | (m) | $10.00M | $10.00M | $3.58B | $10.00M | $21.00M | $5.07B | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 9 month · 5.00% | (m) | (m) |
| 2025-09-30 | (m) | $45.00M | $8.78B | $8.83B | $10.00M | $10.00M | $3.57B | $10.00M | (m) | (m) | $32.00M | (m) | (m) | $86.00M | (m) |
| 2025-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 6 month · 5.00% | (m) | (m) |
| 2025-06-30 | (m) | $115.00M | $8.78B | $8.90B | $10.00M | $10.00M | $3.57B | $10.00M | (m) | (m) | $104.00M | (m) | (m) | $90.00M | (m) |
| 2025-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 3 month · 5.10% | (m) | (m) |
| 2025-03-31 | $20.00M | (m) | $8.94B | $8.96B | $25.00M | $62.00M | $3.49B | $9.00M | (m) | (m) | $6.00M | (m) | (m) | $93.00M | (m) |
| 2024-12-31 | (m) | $20.00M | $8.86B | $8.88B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $97.00M | (m) |
| 2024-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 12 month · 5.10% | (m) | (m) |
| 2024-12-31 | $20.00M | (m) | (m) | (m) | $8.00M | $25.00M | $62.00M | $3.44B | $9.00M | $5.42B | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 9 month · 5.30% | (m) | (m) |
| 2024-09-30 | $10.00M | (m) | $8.74B | $8.75B | $9.00M | $10.00M | $9.00M | $4.28B | (m) | (m) | $2.00M | $8.64B | (m) | $105.00M | (m) |
| 2024-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 6 month · 5.40% | (m) | (m) |
| 2024-06-30 | $9.00M | (m) | $8.65B | $8.66B | $9.00M | $9.00M | $9.00M | $4.19B | (m) | (m) | $5.00M | $8.33B | (m) | $108.00M | (m) |
| 2024-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 3 month · 5.70% | (m) | (m) |
| 2024-03-31 | $9.00M | (m) | $8.71B | $8.71B | $9.00M | $9.00M | $9.00M | $6.75B | (m) | (m) | $7.00M | $8.32B | (m) | $79.00M | (m) |
| 2023-12-31 | $9.00M | (m) | $8.75B | $8.76B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $84.00M | (m) |
| 2023-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $8.25B | (m) | (m) | (m) |
| 2023-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 12 month · 5.70% | (m) | (m) |
| 2023-12-31 | (m) | (m) | (m) | (m) | $9.00M | $10.00M | $10.00M | $9.00M | $6.80B | $2.00B | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 9 month · 5.70% | (m) | (m) |
| 2023-09-30 | $8.00M | (m) | $8.65B | $8.65B | $2.00M | $9.00M | $9.00M | $9.00M | $9.00M | $8.70B | (m) | $7.85B | (m) | $87.00M | (m) |
| 2023-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 6 month · 5.60% | (m) | (m) |
| 2023-06-30 | $8.00M | (m) | $8.72B | $8.73B | $4.00M | $10.00M | $10.00M | $10.00M | $9.00M | $8.78B | (m) | $8.04B | (m) | $93.00M | (m) |
| 2023-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 3 month · 5.40% | (m) | (m) |
| 2023-03-31 | $8.00M | (m) | $8.70B | $8.71B | $6.00M | $9.00M | $9.00M | $9.00M | $9.00M | $8.77B | (m) | $8.24B | (m) | $97.00M | (m) |
| 2022-12-31 | $8.00M | (m) | $8.90B | $8.91B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $8.29B | (m) | $105.00M | (m) |
| 2022-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 12 month · 4.90% | (m) | (m) |
| 2022-12-31 | (m) | (m) | (m) | (m) | $8.00M | $9.00M | $9.00M | $9.00M | $9.00M | $8.97B | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 3 month · 4.50% | (m) | (m) |
| 2022-09-30 | $8.00M | (m) | $8.69B | $8.70B | $8.00M | $8.00M | $8.00M | $11.00M | (m) | (m) | $2.00M | $7.77B | (m) | $106.00M | (m) |
| 2022-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 3 month · 4.00% | (m) | (m) |
| 2022-06-30 | $9.00M | (m) | $8.88B | $8.89B | $9.00M | $9.00M | $9.00M | $12.00M | (m) | (m) | $2.00M | $8.10B | (m) | $113.00M | (m) |
| 2022-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 3 month · 3.90% | (m) | (m) |
| 2022-03-31 | $9.00M | (m) | $9.09B | $9.09B | $9.00M | $9.00M | $37.00M | $43.00M | (m) | (m) | $7.00M | $9.00B | (m) | $119.00M | (m) |
| 2021-12-31 | $9.00M | (m) | $9.12B | $9.13B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $9.41B | (m) | $124.00M | (m) |
| 2021-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 3 month · 3.90% | (m) | (m) |
| 2021-12-31 | (m) | (m) | (m) | (m) | $9.00M | $9.00M | $9.00M | $37.00M | $43.00M | $9.15B | (m) | (m) | (m) | (m) | $19.00M |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 3 month · 3.90% | (m) | (m) |
| 2021-09-30 | $39.00M | (m) | $9.26B | $9.30B | $39.00M | $39.00M | $39.00M | $39.00M | (m) | (m) | $10.00M | $9.60B | (m) | $130.00M | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 3 month · 3.00% | (m) | (m) |
| 2021-06-30 | $39.00M | (m) | $9.31B | $9.35B | $39.00M | $39.00M | $39.00M | $39.00M | (m) | (m) | $19.00M | $9.60B | (m) | $135.00M | (m) |
| 2020-12-31 | $0.00 | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |